{ "FullStudy":{ "Rank":217569, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01519687", "OrgStudyIdInfo":{ "OrgStudyId":"PRS-TOFS-G201" }, "Organization":{ "OrgFullName":"Pharmos", "OrgClass":"INDUSTRY" }, "BriefTitle":"Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout", "OfficialTitle":"Open-Label, Inpatient Study of Levotofisopam 50 mg TID Administered for 7 Days to Men and Postmenopausal Women With Hyperuricemia and Gout" }, "StatusModule":{ "StatusVerifiedDate":"January 2012", "OverallStatus":"Unknown status", "LastKnownStatus":"Recruiting", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"January 2012" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"June 2012", "PrimaryCompletionDateType":"Anticipated" }, "CompletionDateStruct":{ "CompletionDate":"June 2012", "CompletionDateType":"Anticipated" }, "StudyFirstSubmitDate":"January 24, 2012", "StudyFirstSubmitQCDate":"January 26, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 27, 2012", "StudyFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"January 26, 2012", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"January 27, 2012", "LastUpdatePostDateType":"Estimate" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor" }, "LeadSponsor":{ "LeadSponsorName":"Pharmos", "LeadSponsorClass":"INDUSTRY" } }, "OversightModule":{ "OversightHasDMC":"No" }, "DescriptionModule":{ "BriefSummary":"The purpose of this study is to determine whether levotofisopam is safe and effective in the treatment of hyperuricemia and gout.", "DetailedDescription":"The primary objectives of this study are (1) to evaluate the safety and tolerability of levotofisopam in patients with hyperuricemia and gout, and (2) to evaluate the effect of treatment with levotofisopam on serum urate levels in these patients." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Hyperuricemia", "Gout" ] }, "KeywordList":{ "Keyword":[ "hyperuricemia", "gout", "levotofisopam" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 2" ] }, "DesignInfo":{ "DesignInterventionModel":"Single Group Assignment", "DesignPrimaryPurpose":"Treatment", "DesignMaskingInfo":{ "DesignMasking":"None (Open Label)" } }, "EnrollmentInfo":{ "EnrollmentCount":"20", "EnrollmentType":"Anticipated" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"Levotofisopam", "ArmGroupType":"Experimental", "ArmGroupDescription":"All patients will receive a single dose of 50 mg on Day 1, 50 mg three times a day (TID) on Days 2 through 6, and a single dose of 50 mg on Day 7. Each dose of study drug will be administered by authorized site personnel throughout the 7-day inpatient treatment period.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: levotofisopam" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"levotofisopam", "InterventionDescription":"50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Levotofisopam" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "S-tofisopam" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Percentage reduction in serum urate", "PrimaryOutcomeDescription":"The primary efficacy variable is the percentage reduction in serum urate from baseline to Day 7 on treatment with levotofisopam.", "PrimaryOutcomeTimeFrame":"Days 1-7" } ] }, "SecondaryOutcomeList":{ "SecondaryOutcome":[ { "SecondaryOutcomeMeasure":"Absolute reduction in serum urate from baseline", "SecondaryOutcomeDescription":"Secondary efficacy variables include absolute reduction in serum urate from baseline to Day 7 on treatment with levotofisopam, proportion of subjects with serum urate < 6 mg/dL on Day 7, change in fractional excretion of urate from baseline to Day 6, and change in 24-hour urinary uric acid from baseline to Day 6.", "SecondaryOutcomeTimeFrame":"Days 1-7" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nProvide voluntary, signed informed consent.\nMale or postmenopausal or surgically sterile females, 18 to 65 years of age, inclusive. Female participants must have been amenorrheic for a minimum of 12 months and must have a negative pregnancy test result within 3 days before administration of levotofisopam. Surgically sterile females are defined as those who have had a hysterectomy, bilateral ovariectomy, or bilateral tubal ligation. Male subjects must agree to practice a medically acceptable form of contraception for the duration of the study and for 30 days after receiving the last dose of levotofisopam.\nPhysician diagnosis of gout with at least one gout flare in the last 6 months, at least one chronically swollen joint due to gout, or presence of a tophus.\nSerum urate level ≥ 8.0 mg/dL and ≤ 12.0 mg/dL after having stopped all urate-lowering therapy for at least 10 days. Serum urate level must also be > 7.7 mg/dL and ≤ 12.0 mg/dL on Day -3 and on Day -2.\nWilling and able to discontinue urate-lowering therapy starting at the screening visit (14-21 days before receiving study drug) through to the follow-up visit (up to 10 days after discharge from the study unit), for a total time off urate-lowering therapy of up to approximately 5 weeks.\nIn the opinion of the investigator, able to participate in all scheduled evaluations, likely to complete all required tests, and likely to be compliant.\nMedications permitted for the treatment of non-excluded medical conditions (other than gout) must be at stable doses for at least 14 days prior to baseline.\nPermitted concurrent general medical conditions must be stable and well controlled.\nWritten and oral fluency in the English language.\n\nExclusion Criteria:\n\nPrevious treatment with racemic tofisopam (RS-tofisopam), levotofisopam (S-tofisopam), or dextofisopam (R-tofisopam).\nKnown or suspected hypersensitivity to any benzodiazepine.\nHistory of two or more clinically significant drug allergies.\nClinically significant infection within 30 days prior to screening or between screen and admission.\nHistory or presence of clinically significant medical disease that might compromise the study or be detrimental to the patient, such as hepatitis (patient excluded if hepatitis A was present within 2 years before screening or if there is any history of hepatitis B or C), human immunodeficiency virus (HIV) infection, uncontrolled diabetes mellitus, cirrhosis, active biliary disease (bile ducts or gallbladder), or moderate or severe chronic kidney disease (estimated glomerular filtration rate < 60 mL/min/1.73 m2).\nPresence of a gout flare during screening or the procedure window.\nHistory or presence of nephrolithiasis.\nHistory or presence of malignancy other than localized basal cell cancer, squamous cell skin cancer, or cancer in situ that has been resected within 5 years.\nClinically significant head trauma with loss of consciousness within 10 years prior to screen.\nMyocardial infarction, congestive heart failure, or known coronary artery disease within 5 years prior to screen.\nAny history of cerebrovascular accident.\nHistory of seizure disorder other than a single childhood febrile seizure.\nAlcohol or psychoactive substance abuse or dependence, as defined by DSM-IV, within 1 year prior to screen, or alcohol use exceeding 21 units per week (on average) in the 3 months preceding screen.\nUsed any tobacco- or nicotine-containing product more days than not within 30 days prior to screening or between screen and admission.\nRegular consumption (e.g., more days than not) of excessive quantities of caffeine-containing beverages (e.g., more than eight cups of coffee or equivalent per day) within 30 days prior to screening or between screen and admission.\nHistory of suicide attempt, any suicidal behavior within 6 months prior to screening or between screen and baseline, or, in the opinion of the investigator, clinically significant risk of suicide or violent behavior.\nHistory or presence of a clinically significant psychiatric disorder or symptom (e.g., delusions, hallucinations) that is likely to compromise the study (e.g., confound study results) or be detrimental to the patient.\nHistory of difficulty donating blood, or history or presence of clinically significant bleeding or hemorrhagic tendencies.\nDonation of blood or plasma within 90 days prior to screening or between screening and admission.\nUncontrolled hypertension (systolic blood pressure > 160 mmHg and/or diastolic > 95 mmHg) or heart rate either < 50 BPM or > 100 BPM at any evaluation prior to the first dose of test drug.\nPregnancy, lactation, a positive pregnancy test result during the screening or admission evaluation.\nA clinically significant abnormality on the screening physical examination, 12-lead electrocardiogram (ECG), or laboratory evaluations.\nA corrected QT (QTcF) value > 450 msec (males) or > 470 msec (females) at screening, admission (Day -3), or baseline (Day -1).\nAspartate aminotransferase or alanine aminotransferase levels > 2 times upper limit of normal (ULN), alkaline phosphatase > 1.5 times ULN, creatinine outside the limits of normal, triglycerides > 500 mg/dL, or thyroid-stimulating hormone (TSH) levels greater than 6.0 µIU/L at screening, admission (Day -3), or Day -2.\nA finding of opiates, amphetamines, cocaine, cannabis, or phencyclidine on the urine drug screen (UDS). Any other positive UDS result must be discussed by the investigator and medical monitor prior to potentially allowing participation of the subject in the study.\nA positive HIV, hepatitis B, or hepatitis C test.\nInability to take or tolerate colchicine for gout flare prophylaxis (0.6 mg QD or BID).\nRequired use of any of the following from the screening visit through the follow-up visit: aspirin or other nonsteroidal antiinflammatory drugs (other than paracetamol, as noted below), diuretics, medications with known urate-lowering effects (including, but not limited to, fenofibrate, losartan, or vitamin C > 500 mg/day), or urate-lowering therapy other than levotofisopam.\nDietary requirements inconsistent with the study unit's standardized diet.\nBody mass index ≥ 35.\nUse of any investigational treatment within 30 days prior to screening or between screen and admission.\nUse of any psychopharmacologic drug or substance within 7 days of screening or between screen and admission.\nUse of potent CYP3A4 inhibitors or potent CYP3A4 inducers within 7 days prior to screening or between screen and admission.\nAn estimated 24-hour uric acid excretion > 1,000 mg/day.", "HealthyVolunteers":"No", "Gender":"All", "MinimumAge":"18 Years", "MaximumAge":"65 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "CentralContactList":{ "CentralContact":[ { "CentralContactName":"John S. Sundy, MD, PhD", "CentralContactRole":"Contact", "CentralContactPhone":"(919) 684-2347", "CentralContactEMail":"john.sundy@duke.edu" },{ "CentralContactName":"Lou Cappoli, MBA", "CentralContactRole":"Contact", "CentralContactPhone":"(919) 684-4888", "CentralContactEMail":"lou.cappoli@duke.edu" } ] }, "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"John S. Sundy, MD, PhD", "OverallOfficialAffiliation":"Duke Clinical Research Unit", "OverallOfficialRole":"Principal Investigator" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"Duke Clinical Research Unit (DCRU)", "LocationStatus":"Recruiting", "LocationCity":"Durham", "LocationState":"North Carolina", "LocationZip":"27720", "LocationCountry":"United States", "LocationContactList":{ "LocationContact":[ { "LocationContactName":"John S. Sundy, MD, PhD", "LocationContactRole":"Contact", "LocationContactPhone":"919-684-2347", "LocationContactEMail":"john.sundy@duke.edu" },{ "LocationContactName":"Lou Cappoli", "LocationContactRole":"Contact", "LocationContactPhone":"(919) 684-4888", "LocationContactEMail":"lou.cappoli@duke.edu" },{ "LocationContactName":"John S. Sundy, MD, PhD", "LocationContactRole":"Principal Investigator" },{ "LocationContactName":"Robert Noveck, MD, PhD", "LocationContactRole":"Sub-Investigator" } ] } } ] } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"C000012582", "InterventionMeshTerm":"Tofisopam" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000000928", "InterventionAncestorTerm":"Antidepressive Agents" },{ "InterventionAncestorId":"D000011619", "InterventionAncestorTerm":"Psychotropic Drugs" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M230977", "InterventionBrowseLeafName":"Tofisopam", "InterventionBrowseLeafAsFound":"Levotofisopam", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M2828", "InterventionBrowseLeafName":"Antidepressive Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M13057", "InterventionBrowseLeafName":"Psychotropic Drugs", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"PsychDr", "InterventionBrowseBranchName":"Psychotropic Drugs" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000006073", "ConditionMeshTerm":"Gout" },{ "ConditionMeshId":"D000033461", "ConditionMeshTerm":"Hyperuricemia" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000001168", "ConditionAncestorTerm":"Arthritis" },{ "ConditionAncestorId":"D000007592", "ConditionAncestorTerm":"Joint Diseases" },{ "ConditionAncestorId":"D000009140", "ConditionAncestorTerm":"Musculoskeletal Diseases" },{ "ConditionAncestorId":"D000070657", "ConditionAncestorTerm":"Crystal Arthropathies" },{ "ConditionAncestorId":"D000012216", "ConditionAncestorTerm":"Rheumatic Diseases" },{ "ConditionAncestorId":"D000011686", "ConditionAncestorTerm":"Purine-Pyrimidine Metabolism, Inborn Errors" },{ "ConditionAncestorId":"D000008661", "ConditionAncestorTerm":"Metabolism, Inborn Errors" },{ "ConditionAncestorId":"D000030342", "ConditionAncestorTerm":"Genetic Diseases, Inborn" },{ "ConditionAncestorId":"D000008659", "ConditionAncestorTerm":"Metabolic Diseases" },{ "ConditionAncestorId":"D000010335", "ConditionAncestorTerm":"Pathologic Processes" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M22930", "ConditionBrowseLeafName":"Hyperuricemia", "ConditionBrowseLeafAsFound":"Hyperuricemia", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M7760", "ConditionBrowseLeafName":"Gout", "ConditionBrowseLeafAsFound":"Gout", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M3057", "ConditionBrowseLeafName":"Arthritis", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M9204", "ConditionBrowseLeafName":"Joint Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10680", "ConditionBrowseLeafName":"Musculoskeletal Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M630", "ConditionBrowseLeafName":"Crystal Arthropathies", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M13628", "ConditionBrowseLeafName":"Rheumatic Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M4906", "ConditionBrowseLeafName":"Collagen Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10224", "ConditionBrowseLeafName":"Metabolism, Inborn Errors", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M13123", "ConditionBrowseLeafName":"Purine-Pyrimidine Metabolism, Inborn Errors", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M22270", "ConditionBrowseLeafName":"Genetic Diseases, Inborn", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10222", "ConditionBrowseLeafName":"Metabolic Diseases", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC23", "ConditionBrowseBranchName":"Symptoms and General Pathology" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"BC05", "ConditionBrowseBranchName":"Muscle, Bone, and Cartilage Diseases" },{ "ConditionBrowseBranchAbbrev":"BC16", "ConditionBrowseBranchName":"Diseases and Abnormalities at or Before Birth" },{ "ConditionBrowseBranchAbbrev":"BC18", "ConditionBrowseBranchName":"Nutritional and Metabolic Diseases" },{ "ConditionBrowseBranchAbbrev":"BC17", "ConditionBrowseBranchName":"Skin and Connective Tissue Diseases" } ] } } } } } }